Denali Therapeutics officer Peter Scott Chin proposed selling 1,654 common shares after restricted stock lapsed, with the shares sold to cover a tax obligation from vested Equity compensation. For investors, the stated purpose links the transaction to tax settlement rather than a discretionary sale, while director Nancy Thornberry separately sold 11,439 shares at $22.85-$23.74.

Key Highlights

  • Director Nancy Thornberry sold 11,439 Denali Therapeutics shares in two transactions priced at $22.85-$23.74 each.
  • The proposed sale followed a restricted stock lapse dated 09/03/2026.
  • Morgan Stanley Smith Barney LLC is listed as the executive financial services firm connected with Peter Scott Chin’s transaction.

Denali Therapeutics Inc. (NASDAQ: DNLI) proposed the sale of 1,654 common shares by officer Peter Scott Chin after a restricted stock lapse. The transaction is tied to equity compensation and is intended to cover a tax obligation from vested Restricted Stock Units.

1,654 Shares Linked to Equity Compensation

The transaction was dated 09/03/2026 and associated with Denali Therapeutics common stock. The Form 144 information was dated 09/04/2026, and Morgan Stanley Smith Barney LLC was listed in connection with executive financial services. The related records name Peter Scott Chin as an officer of Denali Therapeutics. Director Nancy Thornberry separately sold 11,439 shares at prices ranging from $22.85 to $23.74 per share across two transactions. That transaction was identified in the source as a Form 4 sale. The records list Denali Therapeutics at 161 Oyster Point Blvd. South San Francisco, California 94,080. Peter Scott Chin’s transaction was signed on 09/04/2026 by Tyler Nielsen under power of attorney.